Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks

Along with rolling out a $1.8 million price tag in Europe, Bluebird Bio said last Friday its newly approved gene therapy would launch in early 2020, later than initial expectations from Wall Street analysts.